Dupixent (dupilumab) has been a breakthrough treatment for people with severe eczema, asthma, and other inflammatory conditions. For many, it has provided relief when other therapies failed. However, ...

Sanofi delivered strong Q3 results despite currency headwinds. The company's dependence on Dupixent is increasing. A broad immunology pipeline and the Blueprint Medicines acquisition should help ...

Sanofi (NASDAQ:SNY) shares traded slightly higher in Paris on Friday after the French drugmaker reported better-than-expected Q3 2025 financial results, thanks mainly to its asthma drug Dupixent, ...

LONDON, Oct 24 (Reuters) - Sanofi (SASY.PA), opens new tab reported stronger than expected third-quarter profit on Friday, boosted by demand for blockbuster asthma drug Dupixent, even as the French ...

Investing.com -- Sanofi reported stronger-than-expected third-quarter results, driven by accelerating demand for its blockbuster drug Dupixent and a wave of new product launches. Shares rose around 3% ...

Sanofi said a jump in sales of its blockbuster Dupixent drug and robust pharmaceutical launches drove higher revenue and adjusted earnings for the third quarter, as the company continues in talks with ...

A 26.2% increase in sales for anti-inflammatory blockbuster Dupixent (dupilumab) ensured Sanofi had a strong Q3, despite the company’s vaccine sales declining amid shifts in US policy. Sanofi is known ...

Sanofi SNY reported third-quarter 2025 adjusted earnings of $1.70 per American depositary share, which beat the Zacks Consensus Estimate of $1.60. Earnings of €2.91 per share rose 7% on a reported ...

The logo of French drugmaker Sanofi is seen a the Sanofi Genzyme Polyclonals in Lyon, France, September 30, 2023. REUTERS/Gonzalo Fuentes LONDON (Reuters) -France's Sanofi reported a third-quarter ...

Six years since the FDA blessed Sanofi and Regeneron’s Dupixent as the first biologic to treat chronic rhinosinusitis with nasal polyps (CRSwNP), a second biologic therapy has broken through with a ...